No Data
Oruka Therapeutics's ORKA-001: Promising Psoriasis Treatment Drives Buy Rating With 12-Month Price Target of $45
Analysts Have Conflicting Sentiments on These Healthcare Companies: Celldex (CLDX), Oruka Therapeutics (ORKA) and Adicet Bio (ACET)
Express News | HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $45 Price Target
Express News | Oruka Therapeutics Inc - Enters License Agreement With Paragon for Worldwide Rights to Orka-001
Express News | Oruka Therapeutics: On Track to Initiate Proof-of-Concept Study in Psoriasis H2 2025, Initial Efficacy Data Expected in H2 2026
Express News | Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of Orka-001, Its Novel Half-Life Extended Anti-Il-23P19 Antibody
Stock_Drift : It’s not allowed north of the Mason Dixon line. Same with sugar in tea and Waffle Houses.
Stock_Drift : And I’m just kidding around.
MARKET-TEST-DUMMY OP Stock_Drift : Damn, that stings a little.
MARKET-TEST-DUMMY OP Stock_Drift : Absolutely! Enjoy it!
Stock_Drift MARKET-TEST-DUMMY OP : Just fun banter, I love the south, except Georgia.
View more comments...